Al Mayadeen English

  • Ar
  • Es
  • x
Al Mayadeen English

Slogan

  • News
    • Politics
    • Economy
    • Sports
    • Arts&Culture
    • Health
    • Miscellaneous
    • Technology
    • Environment
  • Articles
    • Opinion
    • Analysis
    • Blog
    • Features
  • Videos
    • NewsFeed
    • Video Features
    • Explainers
    • TV
    • Digital Series
  • Infographs
  • In Pictures
  • • LIVE
News
  • Politics
  • Economy
  • Sports
  • Arts&Culture
  • Health
  • Miscellaneous
  • Technology
  • Environment
Articles
  • Opinion
  • Analysis
  • Blog
  • Features
Videos
  • NewsFeed
  • Video Features
  • Explainers
  • TV
  • Digital Series
Infographs
In Pictures
  • Africa
  • Asia
  • Asia-Pacific
  • Europe
  • Latin America
  • MENA
  • Palestine
  • US & Canada
BREAKING
Israeli media: The Israeli army detected a missile launch from Yemen
Al Mayadeen's correspondent from Revolution Square in Tehran: Processions from Bahrain, Iraq, and other Arab nations are in attendance
Iranians gather at Tehran’s Revolution Square for the funeral of martyrs of Israeli aggression
Maduro: I call on the Jews to stop the war madness practiced by the Zionist regime led by Netanyahu
Maduro: Every day, 100 people are killed in Palestine, and the West is watching and is complicit
Iran's representative to the United Nations, in a letter to Guterres and the Security Council: The threat of America and the Zionist entity to assassinate the Supreme Leader is state terrorism.
Washington to the Security Council: The goal was to destroy Iran's uranium enrichment capacity and prevent the threat of Tehran obtaining and using a nuclear weapon
Lebanese Health Ministry: 1 woman martyred, 11 wounded in Israeli strike on residential apartment in Nabatieh, South Lebanon.
Al Mayadeen's correspondent: Four civilians injured in Israeli strike that targeted house in Nabatieh al-Fawqa, South Lebanon.
Al Mayadeen's correspondent in South Lebanon: Israeli warplanes launch strikes on regions of al-Mahmoudiyah, al-Khardali

Positive results, risks reported in Alzheimer's new drug

  • By Al Mayadeen English
  • Source: Agencies
  • 30 Nov 2022 12:55
3 Min Read

Full data showing that a new drug can slow cognitive decline in Alzheimer's patients was released by experts.

  • x
  • Deaths were reported at approximately the same rate in both arms of the trial of the drug, which was developed by firms Biogen and Eisai.Source:AFP
    Deaths were reported at approximately the same rate in both arms of the trial of the drug (AFP)

Experts applauded full data released on Wednesday showing that a new drug can slow cognitive decline in Alzheimer's patients but cautioned that the improvements were comparatively small and the treatment could have serious side effects.

Preliminary data from a lecanemab trial revealed that it slowed cognitive decline by 27% over an 18-month period.

The full trial data, published in the New England Journal of Medicine, expands on those findings while also raising concerns about the frequency of "adverse effects", such as brain bleeds and swelling.

According to the findings, 17.3% of patients given the drug experienced brain bleeds, compared to 9% of those having a placebo. In addition, 12.6% of those taking the drug experienced brain swelling, compared to 1.7% in the placebo group.

Read next: New Blood Test Allows for Early Detection of Alzheimer Symptoms

Deaths were reported at roughly the same rate in both arms of the drug trial, which was developed by Biogen and Eisai.

The findings were widely applauded by researchers and advocates for dementia patients, including Bart De Strooper, director of the UK Dementia Research Institute. "This is the first drug that provides a real treatment option for people with Alzheimer's," he said.

Related News

Air pollution linked to increased dementia risk: Harvard report

19-year-old Chinese man becomes youngest patient with Alzheimer's

"While the clinical benefits appear somewhat limited, it can be expected that they will become more apparent if the drug is administered over a longer time period."

Longer trials needed 

Regarding Alzheimer's disease, two key proteins, tau and amyloid beta, build up into tangles and plaques, known together as aggregates, which cause brain cells to die and lead to brain shrinkage.

Lecanemab works by targeting amyloid, and according to De Strooper, the drug not only cleared it but also had "beneficial effects on other hallmarks of Alzheimer's, including tau."

The phase three trial lasted for 18 months and involved nearly 1,800 people who were randomly assigned to either the drug or a placebo.

They were evaluated using an Alzheimer's disease clinical scale that measures cognition and function, as well as changes in amyloid levels and other indicators. However, Tara Spires-Jones, programme lead at the UK Dementia Research Institute, noted that "there is not an accepted definition of clinically meaningful effects in the cognitive test they used."

"It is not clear yet whether the modest reduction in decline will make a big difference to people living with dementia. Longer trials will be needed to be sure that the benefits of this treatment outweigh the risks," she added.

Additionally, the drug only targets those in the early stages of the disease with a certain level of amyloid buildup, limiting the number of people who could potentially benefit from the treatment. And as Alzheimer's is not always caught quickly, some experts said an overhaul in early diagnosis would be needed to ensure more people could benefit.

Previously, Biogen and Eisai put the Alzheimer's drug Aduhelm on the market, but there was significant controversy over the evidence that it worked, and its approval resulted in the resignations of three high-level FDA officials.

  • Alzheimer
  • Lecanemab
  • United Kingdom
  • Alzheimer's Disease

Most Read

Iranian President Masoud Pezeshkian attends a protest following the US attacks on nuclear sites in Iran, in Tehran, Iran, Sunday, June 22, 2025. (AP)

Iran declares victory as ceasefire forces Israeli retreat

  • Politics
  • 24 Jun 2025
Israeli workers survey the site where a missile launched from Iran struck in Haifa on Sunday, June 22, 2025. (AP)

True Promise 3, wave 20: 40 missiles launched, Kheibar-Shekan in first

  • Politics
  • 22 Jun 2025
Iran launches strikes on Israeli targets, despite alleged ceasefire

Iran victorious as ceasefire with 'Israel' takes effect

  • Politics
  • 24 Jun 2025
Iranian worshippers carry their country's flags in a protest to condemn Israeli attacks on multiple cities across Iran, after the Friday prayers ceremony in Tehran, Iran, Friday, June 20, 2025. (AP)

Iran warns of NPT withdrawal, Strait of Hormuz closure after US attack

  • Politics
  • 22 Jun 2025

Coverage

All
The Ummah's Martyrs

Read Next

All
Israeli occupation soldiers search for settlers amid the rubble of buildings destroyed by an Iranian missile strike in Bat Yam, central occupied Palestine, on Sunday, June 15, 2025 (AP)
Politics

Iran missile strike flattens Bat Yam, displaces 2,000 settlers

Palestinian fighters from the Islamic Jihad militant group riding on a truck with weaponry on display take part in an anti-Israel parade marking the 36th anniversary of the movement's founding, in Gaza City, Wednesday, Oct. 4, 2023 (AP)
Politics

Palestinian Resistance attacks Israeli forces in Khan Younis, Jabalia

Iranian Foreign Minister Abbas Araghchi stands waiting to meet Russian President Vladimir Putin for the talks at the Kremlin in Moscow, Russia, Monday, June 23, 2025 (AP)
Politics

Iran suspends IAEA cooperation, Araghchi blames Grossi for attacks

The commander of the Quds Force's Palestine Unit, Brigadier General Mohammad Said Izadi (Illustrated by Mahdi Rtail for Al Mayadeen English)
Politics

Who was Mohammad Said Izadi, head of the Quds Force's Palestine Unit?

Al Mayadeen English

Al Mayadeen is an Arab Independent Media Satellite Channel.

All Rights Reserved

  • x
  • Privacy Policy
  • About Us
  • Contact Us
  • Authors
Android
iOS